Newer antipsychotics no better than older drug in treating child and adolescent schizophreniaSeptember 15, 2008Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH). The study was published online ahead of print September 15, 2008, in the American Journal of Psychiatry. "Schizophrenia and schizophrenia-related disorders are rare in childhood. But when they do occur, those afflicted generally have more severe symptoms and a worse prognosis than those who develop the disorder in adulthood," said NIMH Director Thomas R. Insel, M.D. "The newer atypical antipsychotics are often used to treat these children, but until now, it has been unclear how effective and safe they really are in children. The side effects of the newer medications should be factored into making treatment decisions." The six-year, multisite Treatment of Early Onset Schizophrenia Study (TEOSS) included 116 youth between 8 and 19 years old, diagnosed with early onset schizophrenia spectrum disorder (EOSS). The TEOSS team randomly assigned the children to eight weeks of either olanzapine (Zyprexa) or risperidone (Risperdal)-both new generation atypical antipsychotics-or to the older conventional antipsychotic molindone (Moban) plus benztropine, a medication often used to reduce side effects like uncontrolled shaking or tremor that can be associated with molindone. The children were monitored throughout the study by an NIMH oversight board to ensure their safety.
Response rates after eight weeks of treatment were comparable among the three medications-50 percent of the children taking molindone improved, 46 percent taking risperidone improved, and 34 percent taking olanzapine improved. Children taking olanzapine or risperidone improved within the first two weeks, while the children on molindone improved within three weeks. The treatment groups did differ in side effects. The children taking olanzapine gained about 13 pounds (6 kilograms) during the trial on average, while children taking risperidone gained about 8 pounds (3.6 kilograms), and those taking molindone did not gain weight. The olanzapine group also showed increases in cholesterol levels and other metabolic disruptions that may have become dangerous. The outcome prompted the safety review board to end the olanzapine arm of the study in 2006. "Atypical antipsychotics are commonly used to treat kids with EOSS, but these results question the wisdom of that approach," said lead author Linmarie Sikich, M.D., of the University of North Carolina at Chapel Hill. "They also remind us that we need to develop safer, more effective medications to treat these children, given the limited effectiveness of both the atypical and the conventional medications." Study coauthor Jeffery Lieberman, M.D., of Columbia University Medical Center, noted that TEOSS is the first documented evidence of how newer antipsychotics compare to older ones when treating children and adolescents with schizophrenia. "Doctors need to educate families about the potentially serious side effects these drugs can have so that strategies can be put into place to address them," he reiterated. The TEOSS results are similar to those found in the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), for which Lieberman was the principal investigator. CATIE found that the newer antipsychotics were no more effective than an older antipsychotic in treating adults with schizophrenia. NIH/National Institute of Mental Health | |||||||||||||||||||||
|
Related Schizophrenia Current Events and Schizophrenia News Articles Claudin 11 stops the leaks in neuronal myelin sheaths Devaux and Gow demonstrate how a tight junction protein called claudin 11 makes the neuronal myelin sheath a snug fit. Lower childhood IQ associated with higher risk of adult mental disorders Researchers have hypothesized that people with lower IQs may have a higher risk of adult mental disorders, but few studies have looked at the relationship between low childhood IQ and psychiatric disorders later in life. Prognosis after attempted suicide impaired by psychiatric disorder People who have attempted suicide at some point in their lives are more likely to actually succeed in committing suicide at a later date. Routine Testing After Aneurysm Coiling Carries Low Risk A very low risk of complication is associated with a routine test that determines whether a brain aneurysm treated with endovascular coiling has started to recur, a study led by the University of Cincinnati Neuroscience Institute has shown. Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find Researchers at UT Southwestern Medical Center have uncovered new insights into the "Dr. Jekyll and Mr. Hyde" nature of a protein that stimulates stem-cell maturation in the brain but, paradoxically, can also lead to nerve-cell damage. Pivotal Emory study focuses on teens at risk for psychosis Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder. Interaction between gene variants may alter brain function in schizophrenia A collaborative study led by investigators from Massachusetts General Hospital (MGH) is giving what may be the first look at how interactions between genes underlie a key symptom of schizophrenia, impaired working memory. Mental health linked to stillbirth and newborn deaths Women with a history of serious mental illness are much more likely to have babies that are stillborn or die within the first month of life, new research reveals. Pitt research identifies new target in brain for treating schizophrenia Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug. Research shows raised incidence of psychoses among migrant groups Researchers examining the occurrence of psychoses among migrant groups have shown a raised incidence for all black and ethnic minority subgroups compared with white British counterparts, and reveal that the risk of psychoses for first and second generations varies by ethnicity. More Schizophrenia Current Events and Schizophrenia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||